Associate Dean, Graduate Studies and Research
Associate Professor
Cross appointed, Faculty of Medicine

Dr. Daneshtalab graduated from University of Alberta with her B.Sc. (Pharmacology; 1998) and PhD (Pharmaceutical Sciences; 2005). She completed two post-doctorates, first in John P. Robarts institute for research in London, Ontario (2004-2006; Cell Biology) and second in Memorial University of Newfoundland (2007-2010; Cardiovascular). Her work helped characterize aspects of GPCR signaling, membrane trafficking, and protein-receptor interaction (London), and the multi-factorial mechanisms involved in hemorrhagic stroke development in stroke-prone animal models (Newfoundland).

Research areas of interest:

• Mechanisms of cerebrovascular dysfunction associated with chronic inflammation (particularly autoimmune disease) leading to stroke development
  
• The PK/PD alterations of both cardiovascular and immuno-modulatory drugs with stroke development in the presence and absence of arthritis models
• Role of the pro-inflammatory mediator in promoting therapeutic failure of cardiovascular disease
• The role of disease severity and antihypertensive drug therapy on cardiovascular outcomes in RA patients

Teaching areas of interest: Pharmacokinetics and Pharmacodynamics, General pharmacology

Current projects:

• Development of a hypertensive-arthritic animal model
• Mechanisms of cerebrovascular dysfunction associated with chronic inflammation (particularly autoimmune disease) leading to stroke development
• Molecular signaling associated with cerebrovascular dysfunction leading to loss of function
• Role of IL-17a in cerebrovascular dysfunction

Selected award:

Ignite Research Development Corporation (RDC) Fund

Selected publications:

Shaker MA, Daneshtalab N, Doré JJE, Younes HM.. (2012). Biocompatibility and biodegradability of implantable drug delivery matrices based on novel poly (decane-co-tricarballylate)photocured elastomers. Journal of Bioactive and Compatible Polymers. 27: 78-94.

Smeda JS, Daneshtalab N.. (2011). The effects of poststroke captopril and losartan treatment on cerebral blood flow autoregulation in SHRsp with hemorrhagic stroke. Journal of Cerebral Blood Flow and Metabolism. 31(2): 476-85.

Daneshtalab N, Smeda JS. (2010). Alterations in the modulation of cerebrovascular tone and blood flow by nitric oxide synthases in SHRsp with stroke. Cardiovascular Research. 86(1): 160-8

Contact:

Dr. Noriko Daneshtalab
Tel: 709-864-2683